Protective effect of Ephedra nebrodensis on doxorubicin-induced cardiotoxicity in rats

Iranian Journal of Pharmacology and Therapeutics

Volumn 8, Issue 2, 2009, Pages 61-66

  Shah, S ^a   Mohan, M M ^a   Kasture, S ^a   Sanna, C ^b   Maxia, A ^b  

^a Department of Pharmacology   (India)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Antioxidant enzymes; Cardiac marker enzymes; Doxorubicin; Ecg; Ephedra nebrodensis

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; DOXORUBICIN; EPHEDRA NEBRODENSIS EXTRACT; EVINAL; GLUTATHIONE; LACTATE DEHYDROGENASE; ONCODRIA; PLANT EXTRACT; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; EPHEDRA; EPHEDRA NEBRODENSIS; HEART PROTECTION; HEART RATE; HEART WEIGHT; LIPID PEROXIDATION; NONHUMAN; QT INTERVAL; RAT;

EID: 79251625519     PISSN: 17352657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Blum RH, Carter SK. A new drug with significant clinical activity. Ann Intern Med 1974; 80: 249-56.
2. Calabresi P, Chabner BA. Chemotherapy of neoplastic diseases, Pharmacological Basis of Therapeutics. NY. Pergamon Press Inc. 1990. p. 1203-1263.
3. Abdel-Aleem S, El-merzabani MM, Sayed-Ahmed MM, Taylor DA, Lowe JE. Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J Mol Cell Cardiol 1997; 29: 789-97.
4. Doroshow JH. Anthracycline and anthracenediones, Cancer Chemotherapy and Biotherapy. Philadelphia, USA. Lippincott Raven Publishers. 1996. p. 409-33.
5. Nohl H, Gille L, Stanick K. The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch 1998; 53: 279-85.
6. Paulson DJ. Carnitine deficiency-induced cardiomyopathy. Mol Cell Biochem 1998; 180:33-41.
7. Beanlands RSB, Shaikh NA, Wen W, Dawood F, Ugnat A, Laaughlin MC, et al. Alternation in fatty acid metabolism in adriamycin cardiomyopathy. J Mol Cell Cardiol 1994; 26:109-19.
8. Chatham JC, Cousins JP, Glickson JD. The relationship between cardiac function and metabolism in acute adriamycin-treated perfused rat heart studied by 31P and 13C NMR spectroscopy. J Mol Cell Cardiol 1990; 22:1187-97.
9. Bown D. Encyclopaedia of Herbs and their Uses. Dorling Kindersley, London. 1995.
10. Chopra RN, Nayar SL, Chopra IC. Glossary of Indian Medicinal Plants, New Delhi, India (Including the Supplement). Council of Scientific and Industrial Research, 1986.
11. Yeung H-C. Handbook of Chinese Herbs and Formulas. Los Angeles. Institute of Chinese Medicine, 1985.
12. Danesi R, Tacca MD, Soldan G. Measurement of the S[alpha]-T segment as the most reliable electrocardiogram parameter for the assessment of adriamycin-induced cardiotoxicity in the rat. J Pharm Methods 1986; 16:251-9.
13. Niehaus WG, Samuelsson B. Formation of malondialdehyde from phospholipids arachidonate during microsomal lipid peroxidation. Eur J Biochem 1968; 6:126-30.
14. Jiang ZY, Hunt JY, Wolff SP. Detection of lipid hydroperoxides using the fox method. Anal Biochem 1992; 202:384-9.
15. Ellman GL. Tissue sulphydryl groups. Arch Biochem Biophys 1959; 82:70-7.
16. Saggu H, Cooksey J, Dexter DA. Selective increase in particulate Superoxide dismutase activity in Parkinsonian subtansia nigra. J Neurochem 1989; 53:692-7.
17. Misra HP, Fridovich I. The generation Superoxide radical during the autooxidation of hemoglobin. J Biol Chem 1972; 247:6960-2.
18. Hughes BP. A method for the estimation of serum creatine kinase and its use in comparing creatine kinase and aldolase activity in normal and pathological sera. Clinica Chimica Acta 1962; 7: 597.
19. Arena E, Bionda F, D'Alessndro N, Dusoncher L, Gebbia N, Gerbasi R. DNA, RNA protein synthesis in heart, liver and brain of mice treated with denaturation of adriamycin. Int Res Commun Syst Med Sci 1984; 2:10543-61.
20. Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Hinderson ES. Cardiac ultrastructural changes induced by daunorubucin therapy. Cancer 1973; 32:771-88.
21. Bristow MR, Sagemen WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS, et al. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. Cardiovasc Pharmacol 1980; 2:487-515.
22. Singal PK, Pierce GN. Adriamycin stimulates Ca2+ binding and lipid peroxidation but depress myocardial function. Am J Physiol 1986; 250:H419-24.
23. Singal PK, Panagia V. Direct effect of adriamycin on the rat heart sarcolemma. Res Commun Chem Pathol Pharmacol 1984; 43:67-77.
24. Singal PK, Segstro RU, Singh RP, Kutryk MJ. Changes in lysosomal morphology and enzyme activities during development of adriamycin-induced cardiomyopathy. Can J Cardiol 1985; 1:139-47.
25. Oslan HM, Young DM, Prieur DJ, LeRoy AF, Reagan RL. Electrolyte and oxidation products of certain lipids. J Biol Chem 1974; 174:257-64.
26. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979; 91:710-7.
27. Villani F, Piccinini F, Merelli P, Favalli L. Influence of adriamycin on calcium exchangeability in cardiac muscle and its modification by ouabain. Biochem Pharmacol 1978; 27:985-7.
28. Caroni P, Villani F, Carafoli E. The cardiotoxic antibiotic doxorubicin inhibits the Na+/Ca+ exchange of dog heart sarcolemmal vesicles. FEBS Lett 1981; 130:184-6.
29. Olson HM, Capen CC. Subacute cardiotoxicity of Adriamycin in the rat: Biochemical and ultrastructural investigations. Lab Invest 1977; 37:386-94.
30. Mettler FP, Young DM, Ward JM. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 1977; 37:2705-13.
31. Bachur NR, Gordon SL, Gee MV, Kon H. NADPH-cytochrome P450 reductase activation of quinone anticancer agents to free radicals. Proc Nat Acad Sci USA 1979; 76:954-7.
32. Lee V, Randhawa AK, Singhal PK. Adriamycin induced myocardial dysfunction in vitro is mediated by free radicals. Am J Physiol 1991; 261:H989-95.
33. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 19:165-7.
34. Machlin LJ. Vitamin E, Handbook of Vitamins, New York. Marcel Dekker Inc. 1991. p. 100-144.
35. Jensen RA, Acton EM, Peters JH. Doxorubicin cardiotoxicity in the rat: Comparision of electrocardiogram, transmembrane potential and structural effects. J Cardiovasc Pharmacol 1984; 6:186-200.
36. Van aker SA, Kramer K, Voest EE, Grimbergen JA, Zharg J, Van-Der-Viigh WJ, et al. Doxorubicin induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors. Cancer Chemother Pharmacol 1996; 38:95-101.
37. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. British J Pharmacol 1998; 124:425-7.
38. Olson RD, Boerth RC, Gerber JG, Nies AS. Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci 1981; 29:1393-401.
39. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990; 4:3076-86.
40. Goormaghtigh E, Ruysschaert JM. Anthracycline glycosides-membrane interactions. Biochem Biophys Acta 1984; 779:271-88.
41. Haenen GRMM, Janssen FP, Bast A. The antioxidant properties of five (O-ß hydroxyethyl) rutosides of the flavonoid mixture Venoruton. Phlebol Suppl 1993; 1:10-7.
42. Van Acker SA, Voest EE, Beems DB, Madhuizen HT, De Jong J, Bast A, et al. Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxirubcin-pretreated BALB/ c mice. Cancer Res 1993; 53:4603-7.